Record ID: MS-N094
Family: Botanicals and supportive care
Clinical question: Does Boswellia serrata reduce radiotherapy-related cerebral edema in people with primary or metastatic brain tumors?
Evidence label: Small randomized pilot; imaging signal without confirmed clinical benefit
Evidence at a glance
Benefit: A larger proportion achieved greater than 75% MRI edema reduction.
Certainty: Low because the trial was small and the clinical secondary endpoints were negative.
Risk: Minor gastrointestinal discomfort was more common; formulation variability and medicine interactions remain concerns.
Cancer control: Edema reduction is supportive care and does not establish tumor control.
What was studied
A prospective double-blind pilot trial randomized 44 patients with primary or secondary malignant brain tumors receiving radiotherapy to Boswellia serrata extract 4,200 mg/day or placebo. The primary endpoint was edema volume on T2-weighted MRI after radiotherapy.
Secondary outcomes included toxicity, cognition, quality of life and dexamethasone use. The dose describes the trial formulation, not a general supplement recommendation.
What the results mean
A greater than 75% reduction in MRI edema occurred in 60% of the Boswellia group and 26% of placebo recipients (P=.023).
Boswellia did not significantly change dexamethasone dose, quality of life or cognitive function. The authors suggested possible steroid-sparing potential, but that clinical benefit was not demonstrated.
Limits and uncertainty
This was a 44-person pilot with a radiographic primary endpoint. Larger prospective studies are needed, and edema can fluctuate with tumor course, radiation effect and steroid management.
The investigators speculated about an antitumor effect, but the trial was not designed to establish response, progression or survival.
Safety and practical context
No severe adverse events were reported; six Boswellia recipients reported minor gastrointestinal discomfort. Later observational formulations cannot be treated as confirmation of this randomized trial.
Cerebral edema can be urgent. New or worsening headache, vomiting, weakness, seizures, confusion or drowsiness needs prompt clinical assessment. Do not adjust dexamethasone without the treating team.
Questions for the care team
- Is the swelling tumor-related, radiation-related or another emergency?
- What clinical goal matters: symptoms, steroid reduction or MRI volume?
- Does the available product match the studied extract?
- How will symptoms, imaging and steroid toxicity be monitored?
Sources
- Randomized pilot trial (PMID 21287538)
- 2025 review of Boswellia for radiation edema/necrosis (PMID 40092573)
Funding and conflicts
Complete funding and conflict details were not verified from the accessible abstract. Product standardization and any manufacturer role should be checked in the full report.
Last literature search: October 21, 2026
Record appraised: October 21, 2026
This educational record is not individualized medical advice. Research doses and schedules are not personal prescriptions; do not delay or replace evidence-based cancer care.
